SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Drug combinations are becoming a standard treatment of many complex diseases due to their capability to overcome resistance to monotherapy. In the current preclinical drug combination screening, the top combinations for further study are often selected based on synergy alone, without considering the combination efficacy and toxicity effects, even though these are critical determinants for the clinical success of a therapy. To promote the prioritization of drug combinations based on integrated analysis of synergy, efficacy and toxicity profiles, we implemented a web-based open-source tool, SynToxProfiler (Synergy-Toxicity-Profiler). When applied to 20 anti-cancer drug combinations tested both in healthy control and T-cell prolymphocytic leukemia (T-PLL) patient cells, as well as to 77 anti-viral drug pairs tested in Huh7 liver cell line with and without Ebola virus infection, SynToxProfiler prioritized as top hits those synergistic drug pairs that showed higher selective efficacy (difference between efficacy and toxicity), which offers an improved likelihood for clinical success.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
Yadav, B., Wennerberg, K., Aittokallio, T., & Tang, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.09.001 · Cited by 845
Self-citationPalmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen
Ramón-García, S., Ng, C., Anderson, H., Chao, J. D., Zheng, X., Pfeifer, T., Av-Gay, Y., Roberge, M., & Thompson, C. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-11 · Cited by 185
Gustafsson, F., Foster, A. J., Sarda, S., Bridgland-Taylor, M. H., & Kenna, J. G. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kft223 · Cited by 77
Cited by
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
Ianevski, A., Giri, A. K., & Aittokallio, T. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa216 · Cited by 873
Self-citationIanevski, A., Giri, A. K., & Aittokallio, T. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac382 · Cited by 778
Self-citationIndependent Drug Action in Combination Therapy: Implications for Precision Oncology
Plana, D., Palmer, A. C., & Sorger, P. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0212 · Cited by 307
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Brennan, P. N., Elsharkawy, A. M., Kendall, T. J., Loomba, R., Mann, D. A., & Fallowfield, J. A. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00796-x · Cited by 68
“Key challenges will be identifying which patient subphenotypes are likely to respond best to certain combinations, defining the chronology of regimens (that is, overlapping, outlasting or additive), and navigating a more complex route to regulatory approval 98 .”
BackgroundDrug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
White, J. M., Schiffer, J. T., Bender Ignacio, R. A., Xu, S., Kainov, D., Ianevski, A., Aittokallio, T., Frieman, M., Olinger, G. G., & Polyak, S. J. (2021) · mBio · doi:10.1128/mbio.03347-21 · Cited by 64
Self-citation
Metadata
- Authors
- Ianevski, A., Timonen, S., Kononov, A., Aittokallio, T., & Giri, A. K.
- Venue
- PLOS Computational Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-02-03
- Volume
- 16
- Issue
- 2
- Pages
- e1007604
- ISSN
- 1553-734X (ISSN-L)
- 1553-7358
- OpenAlex
- W3003840025
- Cited by
- 68
- References
- 6
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.